Nicox S.A. (NICXF)
USD 0.25
(0.0%)
USD 0.25
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 52.98 Million EUR | -46.87% |
| 2022 | 99.7 Million USD | -23.46% |
| 2021 | 130.26 Million USD | -25.16% |
| 2020 | 174.06 Million USD | 8.59% |
| 2019 | 160.29 Million USD | 15.66% |
| 2018 | 138.59 Million EUR | -8.1% |
| 2017 | 150.8 Million EUR | 1.38% |
| 2016 | 148.74 Million EUR | -8.94% |
| 2015 | 163.34 Million EUR | 8.87% |
| 2014 | 150.04 Million EUR | 107.88% |
| 2013 | 72.17 Million EUR | -14.22% |
| 2012 | 84.14 Million EUR | -12.19% |
| 2011 | 95.82 Million EUR | -15.14% |
| 2010 | 112.93 Million EUR | -28.26% |
| 2009 | 157.42 Million EUR | 27.35% |
| 2008 | 123.61 Million EUR | -34.75% |
| 2007 | 189.46 Million EUR | 107.27% |
| 2006 | 91.4 Million EUR | 79.99% |
| 2005 | 50.78 Million EUR | -17.17% |
| 2004 | 61.31 Million EUR | 20.98% |
| 2003 | 50.68 Million EUR | -27.0% |
| 2002 | 69.42 Million EUR | -11.02% |
| 2001 | 78.02 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q4 | 52.98 Million EUR | 0.0% |
| 2023 Q1 | 82.28 Million EUR | -17.48% |
| 2023 Q2 | 89.74 Million USD | 9.07% |
| 2023 FY | 52.98 Million EUR | -46.87% |
| 2022 Q2 | 104 Million EUR | -5.27% |
| 2022 Q4 | 99.7 Million USD | 7.03% |
| 2022 FY | 99.7 Million USD | -23.46% |
| 2022 Q1 | 109.79 Million EUR | -4.2% |
| 2022 Q3 | 93.16 Million EUR | -10.42% |
| 2021 Q3 | 132.74 Million EUR | -0.46% |
| 2021 Q1 | 156.33 Million EUR | 9.89% |
| 2021 Q2 | 133.35 Million EUR | -14.7% |
| 2021 FY | 130.26 Million USD | -25.16% |
| 2021 Q4 | 114.6 Million EUR | -13.66% |
| 2020 Q2 | 149.09 Million EUR | -9.26% |
| 2020 FY | 174.06 Million USD | 8.59% |
| 2020 Q1 | 164.3 Million EUR | 15.06% |
| 2020 Q3 | 166.82 Million EUR | 11.89% |
| 2020 Q4 | 142.26 Million EUR | -14.72% |
| 2019 Q4 | 142.8 Million EUR | -8.26% |
| 2019 FY | 160.29 Million USD | 15.66% |
| 2019 Q3 | 155.66 Million EUR | 10.35% |
| 2019 Q2 | 141.06 Million EUR | -10.85% |
| 2019 Q1 | 158.22 Million EUR | 14.17% |
| 2018 Q3 | 160.88 Million EUR | 9.44% |
| 2018 Q2 | 147 Million EUR | -18.82% |
| 2018 FY | 138.59 Million EUR | -8.1% |
| 2018 Q1 | 181.08 Million EUR | 20.08% |
| 2018 Q4 | 138.59 Million EUR | -13.86% |
| 2017 Q4 | 150.8 Million EUR | -15.39% |
| 2017 Q3 | 178.23 Million EUR | 33.94% |
| 2017 Q2 | 133.07 Million EUR | -6.27% |
| 2017 FY | 150.8 Million EUR | 1.38% |
| 2017 Q1 | 141.97 Million EUR | -4.55% |
| 2016 FY | 148.74 Million EUR | -8.94% |
| 2016 Q4 | 148.74 Million EUR | -10.97% |
| 2016 Q3 | 167.08 Million EUR | 19.55% |
| 2016 Q2 | 139.76 Million EUR | -12.19% |
| 2016 Q1 | 159.17 Million EUR | -2.56% |
| 2015 Q3 | 182.29 Million EUR | 2.82% |
| 2015 FY | 163.34 Million EUR | 8.87% |
| 2015 Q4 | 163.34 Million EUR | -10.39% |
| 2015 Q2 | 177.29 Million EUR | -6.91% |
| 2015 Q1 | 190.46 Million EUR | 26.94% |
| 2014 Q3 | 189.36 Million EUR | 242.57% |
| 2014 Q1 | 76.16 Million EUR | 5.52% |
| 2014 Q2 | 55.27 Million EUR | -27.42% |
| 2014 FY | 150.04 Million EUR | 107.88% |
| 2014 Q4 | 150.04 Million EUR | -20.76% |
| 2013 FY | 72.17 Million EUR | -14.22% |
| 2013 Q4 | 72.17 Million EUR | 2.48% |
| 2013 Q3 | 70.43 Million EUR | -5.47% |
| 2013 Q2 | 74.5 Million EUR | -5.51% |
| 2013 Q1 | 78.85 Million EUR | -6.29% |
| 2012 Q3 | 90.48 Million EUR | -3.82% |
| 2012 Q4 | 84.14 Million EUR | -7.01% |
| 2012 FY | 84.14 Million EUR | -12.19% |
| 2012 Q1 | 100.61 Million EUR | 4.99% |
| 2012 Q2 | 94.08 Million EUR | -6.49% |
| 2011 Q3 | 100.09 Million EUR | -2.39% |
| 2011 Q4 | 95.82 Million EUR | -4.26% |
| 2011 Q1 | 106.31 Million EUR | -5.86% |
| 2011 Q2 | 102.53 Million EUR | -3.55% |
| 2011 FY | 95.82 Million EUR | -15.14% |
| 2010 Q3 | 123.75 Million EUR | -10.77% |
| 2010 Q2 | 138.69 Million EUR | -7.29% |
| 2010 Q1 | 149.59 Million EUR | 0.0% |
| 2010 FY | 112.93 Million EUR | -28.26% |
| 2010 Q4 | 112.93 Million EUR | -8.74% |
| 2009 FY | 157.42 Million EUR | 27.35% |
| 2008 FY | 123.61 Million EUR | -34.75% |
| 2007 FY | 189.46 Million EUR | 107.27% |
| 2006 FY | 91.4 Million EUR | 79.99% |
| 2005 FY | 50.78 Million EUR | -17.17% |
| 2004 FY | 61.31 Million EUR | 20.98% |
| 2003 FY | 50.68 Million EUR | -27.0% |
| 2002 FY | 69.42 Million EUR | -11.02% |
| 2001 FY | 78.02 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 1.87 Million USD | -2721.267% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -10516.405% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -20177.33% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -401.99% |
| GB Sciences, Inc. | 103.44 Thousand USD | -51117.107% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -492.011% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -296208.725% |
| Skye Bioscience, Inc. | 11.94 Million USD | -343.703% |
| Zenith Capital Corp. | 7410.00 USD | -714879.757% |
| Agentix Corp. | 261.39 Thousand USD | -20168.409% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -2605.561% |
| Biomind Labs Inc. | 73.81 Thousand USD | -71670.14% |
| ContraFect Corporation | 20.67 Million USD | -156.202% |
| CSL Limited | 38.02 Billion USD | 99.861% |
| CytoDyn Inc. | 11.13 Million USD | -375.754% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -6774.77% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -89.593% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -10924.707% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -73112.188% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -14882.311% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 59.312% |
| SQZ Biotechnologies Company | 107.18 Million USD | 50.572% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -1499.149% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -36.381% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -3599.638% |
| Mesoblast Limited | 667.9 Million USD | 92.068% |
| Marizyme, Inc. | 22.01 Million USD | -140.653% |
| Genus plc | 1.02 Billion USD | 94.851% |
| Pharming Group N.V. | 462.85 Million USD | 88.554% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -8349.761% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -13762.687% |
| IMV Inc. | 31.33 Million USD | -69.083% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -1177.851% |
| MultiCell Technologies, Inc. | 126.22 USD | -41974230.534% |
| ONE Bio Corp. | 70.08 Million USD | 24.407% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 58.774% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -50.601% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -3556.711% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -76.512% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -1829.116% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -7606.339% |
| Alpha Cognition Inc. | 2.45 Million USD | -2060.535% |
| Enzolytics Inc. | 361.7 Million USD | 85.353% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 98.834% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -11.065% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -8182.577% |
| Genscript Biotech Corporation | 3.38 Billion USD | 98.435% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -633.819% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -69287.327% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -16363.335% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -20170.58% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -5609.292% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -3800.312% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -13471.879% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -5538.036% |
| Helix BioMedix, Inc. | 3.02 Million USD | -1651.355% |
| EV Biologics, Inc. | 431.71 Thousand USD | -12172.013% |
| Q BioMed Inc. | 3.51 Million USD | -1407.033% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -0.529% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 88.129% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -263.866% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -1935.191% |
| HST Global, Inc. | 1526.00 USD | -3471721.756% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -2293406.494% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -5262.527% |
| Halberd Corporation | 10.13 Thousand USD | -522849.363% |
| Resverlogix Corp. | 8.11 Million USD | -552.865% |
| Cell Source, Inc. | 195.17 Thousand USD | -27045.426% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -232462.223% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.37 Million USD | -618.163% |
| Ember Therapeutics, Inc. | 184.00 USD | -28793378.261% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -85011.168% |
| Kadimastem Ltd | 2.3 Million USD | -2199.399% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -55285.387% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -92694.339% |
| LadRx Corporation | 2.3 Million USD | -2195.611% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -14882.311% |
| Affymax, Inc. | 7.44 Million USD | -611.81% |
| Itoco Inc. | 1.4 Million USD | -3684.091% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -49881.132% |
| Mobile Lads Corp. | 52.00 USD | -101884515.385% |
| International Stem Cell Corporation | 5.39 Million USD | -882.931% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 137.63 Thousand USD | -38392.277% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -36956.207% |
| Qrons Inc. | 420.00 USD | -12614185.714% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -13644.225% |
| SYBLEU INC | 330.46 Thousand USD | -15931.809% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -9495.74% |
| Rebus Holdings, Inc. | 5000.00 USD | -1059500.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -12840.194% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -253.157% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -219.561% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -66963.291% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -6027.143% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -604.802% |
| Neutra Corp. | 2851.00 USD | -1858195.335% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -63.488% |
| PureTech Health plc | 693.97 Million USD | 92.366% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -556.417% |
| IXICO plc | 15.84 Million USD | -234.387% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -539.701% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 48.724% |
| CSL Limited | 38.02 Billion USD | 99.861% |
| Cellectis S.A. | 333.99 Million USD | 84.137% |